Cargando…

Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype

Bruton’s tyrosine-kinase (BTK) is a non-receptor tyrosine kinase recently associated with glioma tumorigenesis and a novel prognostic marker for poor survival in patients with glioma. The p65BTK is a novel BTK isoform involved in different pathways of drug resistance of solid tumors, thus we aimed t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sala, Luca, Cirillo, Giovanni, Riva, Gabriele, Romano, Gabriele, Giussani, Carlo, Cialdella, Annamaria, Todisco, Antonio, Virtuoso, Assunta, Cerrito, Maria Grazia, Bentivegna, Angela, Grassilli, Emanuela, Ardizzoia, Antonio, Bonoldi, Emanuela, Giovannoni, Roberto, Papa, Michele, Lavitrano, Marialuisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353843/ https://www.ncbi.nlm.nih.gov/pubmed/30733667 http://dx.doi.org/10.3389/fnmol.2019.00002

Ejemplares similares

BTK, the new kid on the (oncology) block?
por: Grassilli, Emanuela, et al.
Publicado: (2022)

p65BTK Is a Novel Biomarker and Therapeutic Target in Solid Tumors
por: Grassilli, Emanuela, et al.
Publicado: (2021)

Tumor Microenvironment and Immune Escape in the Time Course of Glioblastoma
por: Virtuoso, Assunta, et al.
Publicado: (2022)

p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma
por: Giordano, Federica, et al.
Publicado: (2019)

Influence of Bruton’s Tyrosine Kinase (BTK) on Epithelial–Mesenchymal Transition (EMT) Processes and Cancer Stem Cell (CSC) Enrichment in Head and Neck Squamous Cell Carcinoma (HNSCC)
por: Leichtle, Franziska, et al.
Publicado: (2023)

Role of Bruton’s Tyrosine Kinase in Stage III Colorectal Cancer
por: Basile, Debora, et al.
Publicado: (2019)

GSK3A Is Redundant with GSK3B in Modulating Drug Resistance and Chemotherapy-Induced Necroptosis
por: Grassilli, Emanuela, et al.
Publicado: (2014)

A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation
por: Grassilli, E, et al.
Publicado: (2016)

Unexpected frequency of genomic alterations in histologically normal colonic tissue from colon cancer patients
por: Conconi, Donatella, et al.
Publicado: (2016)

Editorial: Targeting Bruton Tyrosine Kinase
por: Brunner, Cornelia, et al.
Publicado: (2022)

AhRR and PPP1R3C: Potential Prognostic Biomarkers for Serous Ovarian Cancer
por: Ardizzoia, Alessandra, et al.
Publicado: (2023)

The Glioblastoma Microenvironment: Morphology, Metabolism, and Molecular Signature of Glial Dynamics to Discover Metabolic Rewiring Sequence
por: Virtuoso, Assunta, et al.
Publicado: (2021)

Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate
por: Wang, Qi, et al.
Publicado: (2015)

The TGF-β pathway is activated by 5-fluorouracil treatment in drug resistant colorectal carcinoma cells
por: Romano, Gabriele, et al.
Publicado: (2016)

Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption
por: Ariza, Yuko, et al.
Publicado: (2019)

Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data
por: Villa, Federica, et al.
Publicado: (2023)

Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study
por: Cerrito, Maria Grazia, et al.
Publicado: (2018)

Gemistocytic Differentiation in Isocitrate Dehydrogenase Mutant Astrocytomas: A Histopathological and Survival Analysis
por: Hassan, Usman, et al.
Publicado: (2023)

Resveratrol Impairs Glioma Stem Cells Proliferation and Motility by Modulating the Wnt Signaling Pathway
por: Cilibrasi, Chiara, et al.
Publicado: (2017)

Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells
por: Bam, R, et al.
Publicado: (2014)

Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer
por: Zhu, Zhen, et al.
Publicado: (2020)

Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures
por: Ringheim, Garth E., et al.
Publicado: (2021)

Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer
por: Zucha, Muhammad Ary, et al.
Publicado: (2015)

P1239: BRUTON TYROSINE KINASE (BTK) PROTEIN DEGRADER BGB-16673 IS LESS APT TO CAUSE, AND ABLE TO OVERCOME VARIABLE BTK RESISTANCE MUTATIONS COMPARED TO OTHER BTK INHIBITORS (BTKI)
por: Feng, Xiaoyu, et al.
Publicado: (2023)

ZYBT1, a potent, irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer
por: Ghoshdastidar, Krishnarup, et al.
Publicado: (2020)

BTK Isoforms p80 and p65 Are Expressed in Head and Neck Squamous Cell Carcinoma (HNSCC) and Involved in Tumor Progression
por: Betzler, Annika C., et al.
Publicado: (2023)

Effect and Mechanism of the Bruton Tyrosine Kinase (Btk) Inhibitor Ibrutinib on Rat Model of Diabetic Foot Ulcers
por: Yang, Xuedong, et al.
Publicado: (2019)

Bruton’s tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma
por: Yeh, Chi-Tai, et al.
Publicado: (2021)

Design, synthesis and evaluation of a series of potential prodrugs of a Bruton’s tyrosine kinase (BTK) inhibitor
por: Xiao, Zhou-Peng, et al.
Publicado: (2023)

Emerging actionable targets to treat therapy-resistant colorectal cancers
por: Grassilli, Emanuela, et al.
Publicado: (2022)

Identifying Novel Actionable Targets in Colon Cancer
por: Cerrito, Maria Grazia, et al.
Publicado: (2021)

“Ironing out” fasting-induced persister cancer cells to render chemotherapy effective: is this the solution?
por: Grassilli, Emanuela, et al.
Publicado: (2023)

In vitro anticancer drug test: A new method emerges from the model of glioma stem cells
por: Riva, Gabriele, et al.
Publicado: (2014)

Bruton's Tyrosine Kinase (BTK) and Vav1 Contribute to Dectin1-Dependent Phagocytosis of Candida albicans in Macrophages
por: Strijbis, Karin, et al.
Publicado: (2013)

Bruton tyrosine kinase (BTK) may be a potential therapeutic target for interstitial cystitis/bladder pain syndrome
por: Wang, Guang, et al.
Publicado: (2022)

Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation
por: Scagliotti, Arianna, et al.
Publicado: (2022)

Diagnosis and clinical outcome following surgical resection of an intracranial grade III anaplastic gemistocytic astrocytoma in a cat
por: Murthy, Vishal D, et al.
Publicado: (2020)

A novel Bruton’s tyrosine kinase gene (BTK) missense mutation in a Chinese family with X-linked agammaglobulinemia
por: Zheng, Bixia, et al.
Publicado: (2014)

Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes
por: Wei, Li, et al.
Publicado: (2016)

Bruton’s Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells
por: Dong, Xing-Duo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i9ut4vcmvhdn1lo3p13puidllp